🚀 VC round data is live in beta, check it out!
Square Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Square Pharma and similar public comparables like Immunocore Holdings, Guangzhou Innogen Pharma, Agios Pharmaceuticals, Trevi Therapeutics and more.
Square Pharma Overview
About Square Pharma
Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceutical products, basic chemical products, animal health products, and crop care products, along with the manufacturing, marketing, and distribution of pharmaceutical products. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs for health care for all living species. It manufactures drugs such as paracetamol, clotrimazole, antiallergic, nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs, and also provides devices such as AnsuPen and AnsuPen Twist.
Founded
1964
HQ
Employees
15.9K
Website
Sectors
Financials (FY)
EV
$1B
Square Pharma Financials
Square Pharma reported last fiscal year revenue of $630M and EBITDA of $232M.
In the same fiscal year, Square Pharma generated $302M in gross profit, $232M in EBITDA, and $198M in net income.
Revenue (LTM)
Square Pharma P&L
In the most recent fiscal year, Square Pharma reported revenue of $630M and EBITDA of $232M.
Square Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $630M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $302M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 48% | XXX | XXX | XXX |
| EBITDA | — | XXX | $232M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 37% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 25% | XXX | XXX | XXX |
| Net Profit | — | XXX | $198M | XXX | XXX | XXX |
| Net Margin | — | XXX | 31% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Square Pharma Stock Performance
Square Pharma has current market cap of $2B, and enterprise value of $1B.
Market Cap Evolution
Square Pharma's stock price is $1.82.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $2B | 0.0% | XXX | XXX | XXX | $0.22 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSquare Pharma Valuation Multiples
Square Pharma trades at 1.8x EV/Revenue multiple, and 5.0x EV/EBITDA.
EV / Revenue (LTM)
Square Pharma Financial Valuation Multiples
As of March 18, 2026, Square Pharma has market cap of $2B and EV of $1B.
Equity research analysts estimate Square Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Square Pharma has a P/E ratio of 8.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 5.0x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 7.2x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3.8x | XXX | XXX | XXX |
| P/E | — | XXX | 8.2x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 12.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Square Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Square Pharma Margins & Growth Rates
Square Pharma's revenue in the last fiscal year grew by 10%.
Square Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 37% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (12%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 23% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Square Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Immunocore Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| Guangzhou Innogen Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Agios Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Trevi Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Nanobiotix | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Square Pharma M&A Activity
Square Pharma acquired XXX companies to date.
Last acquisition by Square Pharma was on XXXXXXXX, XXXXX. Square Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Square Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSquare Pharma Investment Activity
Square Pharma invested in XXX companies to date.
Square Pharma made its latest investment on XXXXXXXX, XXXXX. Square Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Square Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Square Pharma
| When was Square Pharma founded? | Square Pharma was founded in 1964. |
| Where is Square Pharma headquartered? | Square Pharma is headquartered in Bangladesh. |
| How many employees does Square Pharma have? | As of today, Square Pharma has over 15K employees. |
| Is Square Pharma publicly listed? | Yes, Square Pharma is a public company listed on Dhaka Stock Exchange. |
| What is the stock symbol of Square Pharma? | Square Pharma trades under SQURPHARMA ticker. |
| Who are competitors of Square Pharma? | Square Pharma main competitors are Immunocore Holdings, Guangzhou Innogen Pharma, Agios Pharmaceuticals, Trevi Therapeutics. |
| What is the current market cap of Square Pharma? | Square Pharma's current market cap is $2B. |
| What is the current revenue of Square Pharma? | Square Pharma's last fiscal year revenue is $630M. |
| What is the current revenue growth of Square Pharma? | Square Pharma revenue growth (vs. last FY) is 10%. |
| What is the current EV/Revenue multiple of Square Pharma? | Current revenue multiple of Square Pharma is 1.8x. |
| Is Square Pharma profitable? | No, Square Pharma is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.